Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 1,434 shares, a drop of 73.7% from the January 15th total of 5,444 shares. Based on an average daily trading volume, of 25,027 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 25,027 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BRNS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. HC Wainwright boosted their price objective on shares of Barinthus Biotherapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. grew its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 192,461 shares of the company’s stock after buying an additional 100,000 shares during the period. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. 25.20% of the stock is owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Price Performance

Shares of BRNS stock opened at $0.66 on Thursday. The company has a fifty day moving average price of $0.72 and a two-hundred day moving average price of $1.01. Barinthus Biotherapeutics has a one year low of $0.56 and a one year high of $2.92. The stock has a market cap of $26.99 million, a P/E ratio of -0.35 and a beta of -0.66.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.